Screener / RNAi Therapeutics / Alnylam Pharmaceuticals

ALNY · NASDAQ

Alnylam Pharmaceuticals

Compliant

Under AAOIFI Standard 21, Alnylam Pharmaceuticals is compliant. Its core business is permissible and its interest-bearing debt is below 30% of market cap.

TickerALNY
ExchangeNASDAQ
SectorRNAi Therapeutics

Full ratios for Alnylam Pharmaceuticals (impure revenue, debt and interest-bearing deposits under all four standards) are being added. Until then this page shows the screening verdict only. See the methodology for how each test works. Purindex publishes this screening to help people understand what they own. It does not recommend buying, selling or holding Alnylam Pharmaceuticals or any other security.